November 19, 2021 05:50 AM ESTUpdated 03:08 PM

Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Paul Schloesser

Associate Editor

Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite.

The

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Take­da on­col­o­gy vet drills down the 'ba­sic­s' at cell ther­a­py start­up; Sarep­ta pro­motes new R&D chief

Senior Editor

Editor

Associate Editor

Sign up to read this article for free.

Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief